Search results for CancerTherapy
CancerTherapy community
One keyword maps to one global community path.
People
Not Found
Tweets including CancerTherapy
Antibody–Drug Conjugates (ADCs) are shaping the future of targeted cancer therapy with greater precision and reduced toxicity.
📅 Dates: 25–26 May 2026
📍 Location: Rome, Italy
💻Format: Hybrid (In-person + Virtual)
Website:
#ADCs# #CancerTherapy# #OTDC2026#
Show more
DNA-inspired cancer therapy and eye, heart, and psychology tests informing human health wrapped up the week aboard the orbital outpost. More...
LNPs are transforming precision cancer therapy with smarter, targeted delivery.
Join us at (OTDC – May) 25–26, 2026 in Rome, Italy to explore next-gen oligonucleotide innovation.
🔗
#LNP# #OTDC2026# #mRNAtherapy# #siRNADelivery#
Show more
🎯 Stimuli-Responsive Drug Delivery in Cancer Therapy
Breakthroughs in smart delivery platforms triggered by pH, enzymes, temperature, redox cues & more are transforming active and passive cancer targeting.
📍 OTDC 2026 – Rome, Italy
📅 May 25–26, 2026
🔗
Show more
Ingrid Zhang is taking the helm of the cancer therapy company, filling a post vacant since its previous CEO abruptly resigned in July.
Eli Lilly’s blockbuster diabetes drug Mounjaro has surpassed Merck’s cancer therapy Keytruda as the world’s best-selling medication
🔬Aptamers are emerging as precise DNA/RNA tools for targeted cancer therapy and tumor diagnostics.
Excited for the Oligonucleotide Therapeutics & Delivery Conference (OTDC 2026) happening 25–26 May2026, Rome,Italy.
🔗
#OTDC2026# #Aptamers# #CancerResearch#
Show more
MRNA up 177% in a day.
Phase 3 data shows Moderna's mRNA cancer therapy with Merck hit its key trial goals. Not approved yet, but the platform just got real validation.
Full breakdown here:
Show more
$MRNA is now live on Offerbook as collateral.
Moderna and Merck just reported the first positive Phase 3 results for an mRNA-based cancer therapy.
Lend / borrow against MRNA at a fixed rate without liquidations.
Put your MRNA to work onchain.
Show more
Flagship Founder and CEO @NoubarAfeyan joined @LizClaman on @FoxBusiness’ The Claman Countdown to discuss the Phase 3 trial data for @Merck and #FlagshipFounded# @moderna_tx’s mRNA-based therapy for melanoma.
The results mark the first positive Phase 3 trial for an individualized neoantigen therapy and for an mRNA-based cancer therapy — a major milestone for personalized cancer treatment.
Watch the full conversation here:
Show more
